曾经的"私募一哥"徐翔之母郑素贞所持大恒科技股份已全部完成拍卖，这家公司将迎来新的大股东，公司的控制权也将发生变更。 8月6日，大恒科技涨停，报13.26元/股，总市值达57.92亿元。 这一股价异动的背后，是公司控股股东、实际控制人郑素贞所持1.3亿股无限售流通股的司法拍卖落定。同时，以6.29%的持股比例成为主要受让方之一的 李蓉蓉，其身份引发了市场关注。 徐翔母亲不再持有大恒科技股份 经过长达7个多月的等待、501次报价，大恒科技的股权拍卖最终尘埃落定。 8月5日，大恒科技发布公告称，郑素贞所持公司的1.3亿股，占其持股总数100%、公司总股本29.75%的股份，在司法拍卖中被裁定转让，股份拍卖金额合 计达17.12亿元。若此次拍卖股份过户登记顺利完成，郑素贞将不再持有公司股份，公司控制权将发生变更。 | 大恒科技 < > G Q 600288 國 ▼ | | --- | | 13.26 今开 12.00 最高 13.26 最低 12.00 | | 10.04% 1.21 换手 12.61% 总手 55.1万 金额 7.04亿 | | 总值 57.92亿 流值 57.92亿 市盈利 -175.77 更多 ...

Core Viewpoint - The auction of shares held by Zheng Suzhen, the mother of Xu Xiang, has been completed, leading to a change in control of Daheng Technology, with a new major shareholder emerging [1][5][6]. Group 1: Share Auction Details - Zheng Suzhen's 130 million shares, representing 29.75% of Daheng Technology's total shares, were judicially auctioned for a total of 1.712 billion yuan [5][10]. - The auction concluded after 501 bids over more than seven months, with the shares sold at a price of 13.17 yuan per share [5][10]. - The auction involved eight buyers, with Li Rongrong acquiring 27.46 million shares, making her the largest single shareholder with a 6.29% stake [10][11]. Group 2: New Shareholder Profile - Li Rongrong's participation in the auction was based on her recognition of the long-term investment value and future prospects of the company [11]. - Li Rongrong has been employed at Ningbo Jinhai Logistics Service Co., Ltd. since 2018, which is a subsidiary of the Ningbo Customs [11][12]. - Concerns have been raised regarding the source of her substantial funds for the purchase, which were stated to be from her own or raised funds [13]. Group 3: Historical Context and Control Change - The original major shareholder, China New Era Co., Ltd., transferred a significant portion of its shares to Zheng Suzhen in 2014, which later led to the judicial freezing of these shares due to legal issues involving Xu Xiang [6][8]. - The change in control signifies the gradual divestment of assets by the Xu family from Daheng Technology [6][8]. - Following the auction, the company stated that the change in control would not adversely affect its governance structure or operations [17]. Group 4: Company Performance and Future Outlook - Daheng Technology's main business includes machine vision and information technology, with a projected net profit of -4.06 million yuan for the first half of 2025, indicating a reduction in losses [17][18]. - The company reported a revenue of 363 million yuan in the first quarter of 2025, a year-on-year increase of 22.73% [17]. - Daheng Technology ranks third among key enterprises in the Chinese machine vision industry, holding 134 invention patents as of the end of 2024 [18].

金融界8月6日消息，上证指数低开高走，中证沪港深互联互通综合主要消费指数 (沪港深通消费综合， H30482)报10037.55点。 从中证沪港深互联互通综合主要消费指数持仓样本的行业来看，酒占比37.62%、食品占比27.64%、养 殖占比16.77%、软饮料占比8.13%、美容护理占比3.73%、种植占比2.90%、家庭用品占比2.00%、烟草 占比1.22%。 资料显示，该指数系列样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五 的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一 个定期调整日前，权重因子一般固定不变。特殊情况下将对该指数系列样本进行临时调整。当样本退市 时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处 理。当中证沪港深500指数、中证沪港深互联互通中小综合指数和中证沪港深互联互通综合指数样本发 生变动时，将进行相应调整。 数据统计显示，中证沪港深互联互通综合主要消费指数近一个月上涨2.16%，近三个月下跌1.02%，年 至今上涨0.75%。 据了解，中证沪港深行业指数系列将中证沪港深 ...

Core Viewpoint - The auction of shares held by Zheng Suzhen, mother of Xu Xiang, in Daheng Technology (600288) has attracted significant market attention, with the shares sold at a premium price compared to the initial listing price [1] Group 1: Auction Details - Zheng Suzhen's 130 million shares, representing a 29.75% stake in Daheng Technology, were auctioned off after 501 bids, with a final transaction price of 1.712 billion yuan, reflecting a 60.29% premium over the initial listing price of 1.068 billion yuan [1] - The shares were acquired by eight investors, with Li Rongrong emerging as the largest winner, purchasing 27.46 million shares at a price of 13.17 yuan per share, totaling 362 million yuan [1][2] Group 2: Investor Background - Li Rongrong, born in 1975 and residing in Ningbo, Zhejiang Province, has been a mid-level manager at Ningbo Jinhai Logistics Service Co., Ltd. since 2018 [1] - The company, established in 2002 with a registered capital of 7.6 million yuan, is a wholly-owned subsidiary of the Ningbo Customs Logistics Management Center [1] Group 3: Future Plans and Impact - Li Rongrong expressed confidence in the long-term investment value and future prospects of Daheng Technology, stating no plans for shareholding changes or significant adjustments to the company's main business in the next 12 months [2] - The auction significantly impacts Daheng Technology's equity structure, as Zheng Suzhen will no longer hold shares, leading to a change in control [3] - The company maintains that its operations are normal and that the change in control will not adversely affect its governance structure or operations [3]

Core Viewpoint - The auction of shares held by Zheng Suzhen, mother of Xu Xiang, in Daheng Technology (600288) has attracted market attention, with the shares sold at a significant premium over the initial listing price [2]. Group 1: Auction Details - Zheng Suzhen's 130 million shares, representing a 29.75% stake in Daheng Technology, were auctioned off after 501 bids, with a final transaction price of 1.712 billion yuan, reflecting a 60.29% premium over the starting price of 1.068 billion yuan [2]. - The shares were acquired by eight investors, with Li Rongrong emerging as the largest winner, purchasing 27.46 million shares at a price of 13.17 yuan per share, totaling 362 million yuan [2]. Group 2: Investor Background - Li Rongrong, born in 1975 and residing in Ningbo, Zhejiang Province, has been a mid-level manager at Ningbo Jinhai Logistics Service Co., Ltd. since 2018 [2]. - The company, established in 2002 with a registered capital of 7.6 million yuan, is a wholly-owned subsidiary of the Ningbo Customs Logistics Management Center [2]. Group 3: Future Plans and Impact - Li Rongrong expressed confidence in the long-term investment value and future prospects of Daheng Technology, stating no plans for shareholding changes or significant adjustments to the company's main business in the next 12 months [3]. - The auction significantly impacts Daheng Technology's shareholding structure, as Zheng Suzhen will no longer hold any shares, leading to a change in control [4]. - The company confirmed that its operations remain normal and that the change in control will not adversely affect its governance structure or operations [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 萬洲國際有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00288 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.0001 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.0001 | USD | | 5,000,000 | 本月底法定/註冊股本總額： USD 5,000,000 ...

Group 1 - China Biopharmaceutical announced a successful collaboration progress with Merck on LM-299, expecting to receive a $300 million technology transfer milestone payment soon [1] - The technology transfer for LM-299 was completed in July 2025, with Merck confirming the milestone payment in the third quarter [1] - CSPC Pharmaceutical reached an exclusive licensing agreement with Madrigal for the GLP-1 receptor agonist SYH2086, with a total deal value of up to $20.75 billion [2] Group 2 - Eli Lilly's drug Mounjaro (tirzepatide injection) received approval from China's National Medical Products Administration for a new indication to improve blood sugar control in adults with type 2 diabetes [3] - Hualan Pharmaceutical expects a profit of approximately RMB 1.184 billion for the first half of the year, following the successful transfer of commercialization tasks for Huataning [4] - WuXi AppTec reported a 101.92% increase in net profit to RMB 8.561 billion for the first half of the year, with revenue growth of 20.64% to RMB 20.799 billion [5] Group 3 - Heng Rui Medicine signed a collaboration agreement with GSK to advance innovative therapies in respiratory, autoimmune, inflammation, and oncology fields, with a potential total value of approximately $12 billion [6][7] - GSK will pay Heng Rui a $500 million upfront payment, with potential future milestone payments based on successful development and sales [7]

欧洲业务：我们预计2Q25 利润延续同比增长趋势。我们预计肉制品业务保持持续增长，主要系内部提 效和产品结构优化。我们预计2Q25 猪肉业务整体与去年同期盈利情况同比平稳。 盈利预测与估值 我们保持25/26 年核心归母净利润16.14/16.83 亿美元。公司交易在8.1/7.8 倍25/26 年P/E；维持目标价 8.56 港币/股，对应8.7/8.4 倍25/26年P/E和近7.8%上行空间，维持跑赢行业评级。 风险 机构：中金公司 研究员：王文丹/陈文博/武雨欣 我们预计公司2Q25 可比口径营业利润同比低双位数增长我们预计万洲国际可比口径下2Q24 经营利润同 比有望低双位数增长（即剔除2Q24 美国业务中政府补助影响），符合市场预期。 关注要点 中国业务：我们预计2Q25 肉制品销量同比回稳，养殖业务减亏较明显。 1）肉制品：我们预计2Q25 销量同比回稳、吨利受益于成本下降有望同比有所提高。据全国商超数据 2025 年4-5 月份肉制品行业GMV同比-3%，其中双汇GMV同比-1%。2）养殖业务：我们预估1H25 国内 养殖业务进一步减亏，主因饲料成本的下降以及内部提效。3）屠宰：我们预计2Q2 ...

智通财经APP获悉，中金发布研报称，保持万洲国际(00288)25/26年核心归母净利润16.14/16.83亿美 元。公司交易在8.1/7.8倍25/26年P/E;维持目标价8.56港币/股，对应8.7/8.4倍25/26年P/E和近7.8%上行空 间，维持跑赢行业评级。该行预计万洲国际可比口径下2Q24经营利润同比有望低双位数增长(即剔除 2Q24美国业务中政府补助影响)，符合市场预期。 中金主要观点如下： 中国业务：该行预计2Q25肉制品销量同比回稳，养殖业务减亏较明显 1)肉制品：该行预计2Q25销量同比回稳、吨利受益于成本下降有望同比有所提高。据全国商超数据 2025年4-5月份肉制品行业GMV同比-3%，其中双汇GMV同比-1%。2)养殖业务：该行预估1H25国内养 殖业务进一步减亏，主因饲料成本的下降以及内部提效。3)屠宰：该行预计2Q25屠宰业务因去年同期 利润基数偏高同比有所承压。 美国业务：该行预计可比口径下肉制品业务盈利改善(即扣除2Q24政府补助影响)，且养殖业务盈利同比 改善 1)肉制品：该行预计2Q25销售量及吨利均同比有小幅增长，吨利的改善该行预计与公司内部提效有 关，据USDA ...

Group 1: Market Performance - The Hong Kong stock market indices collectively rebounded, with the Hang Seng Index rising by 1.33%, the Hang Seng China Enterprises Index increasing by 1.51%, and the Hang Seng Tech Index gaining 1.65% [1] - The SaaS sector saw significant gains, with companies like Huilyang Technology rising by 15.56%, Yika by 10.11%, and Kingdee International by 7.27% [1] - The stablecoin concept also surged, highlighted by Yaocai Securities rising by 16.93% and Huajian Medical increasing by 20.41% following the U.S. House of Representatives passing a bill to establish a legal framework for stablecoins [1] Group 2: Sector Performance - Gold and non-ferrous metal stocks experienced a broad increase, with Lingbao Gold rising by 6.24% and China Molybdenum by 3.96% as spot gold prices rose above $3340 per ounce [2] - Major financial sectors, including Chinese brokerage and insurance stocks, also saw gains, with Xingsheng International up by 7.41% and China Life by 5.13% [2] Group 3: Automotive and Related Sectors - The automotive sector, including lithium battery and Tesla-related stocks, showed strong performance, with Tianqi Lithium rising by 5.82% and NIO increasing by 4.62% [3] - Other consumer sectors such as film, tobacco, and food stocks also performed well, with companies like Simoer International rising by 4.99% [3] Group 4: Declining Sectors - Sectors such as cosmetics, aviation, and luxury goods saw declines, with China Eastern Airlines dropping by 2.72% [3] - Notably, Chuangmeng Tiandi experienced a significant drop of 30.12%, despite expectations of turning a profit in the first half of the year [3]